These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23537721)

  • 1. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
    Martinowitz U; Lubetsky A
    Thromb Res; 2013 Mar; 131 Suppl 2():S11-4. PubMed ID: 23537721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
    Santagostino E; Martinowitz U; Lissitchkov T; Pan-Petesch B; Hanabusa H; Oldenburg J; Boggio L; Negrier C; Pabinger I; von Depka Prondzinski M; Altisent C; Castaman G; Yamamoto K; Álvarez-Roman MT; Voigt C; Blackman N; Jacobs I;
    Blood; 2016 Apr; 127(14):1761-9. PubMed ID: 26755710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
    Martinowitz U; Lissitchkov T; Lubetsky A; Jotov G; Barazani-Brutman T; Voigt C; Jacobs I; Wuerfel T; Santagostino E
    Haemophilia; 2015 Nov; 21(6):784-90. PubMed ID: 25990590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
    Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
    J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2016 May; 141 Suppl 3():S5-8. PubMed ID: 27288064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats.
    Herzog E; Harris S; Henson C; McEwen A; Schenk S; Nolte MW; Pragst I; Dickneite G; Schulte S; Zollner S
    Thromb Res; 2014 May; 133(5):900-7. PubMed ID: 24680550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
    Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
    J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
    Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B.
    Mancuso ME; Lubetsky A; Pan-Petesch B; Lissitchkov T; Nagao A; Seifert W; Li Y; Santagostino E
    J Thromb Haemost; 2020 May; 18(5):1065-1074. PubMed ID: 32078256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.
    Santagostino E; Negrier C; Klamroth R; Tiede A; Pabinger-Fasching I; Voigt C; Jacobs I; Morfini M
    Blood; 2012 Sep; 120(12):2405-11. PubMed ID: 22859609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.
    Oldenburg J; Yan S; Maro G; Krishnarajah G; Tiede A
    Curr Med Res Opin; 2020 Jan; 36(1):9-15. PubMed ID: 31469321
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.
    Kenet G; Chambost H; Male C; Lambert T; Halimeh S; Chernova T; Mancuso ME; Curtin J; Voigt C; Li Y; Jacobs I; Santagostino E;
    Thromb Haemost; 2016 Sep; 116(4):659-68. PubMed ID: 27583313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
    Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study.
    Kenet G; Chambost H; Male C; Halimeh S; Lambert T; Li Y; Seifert W; Santagostino E
    Thromb Haemost; 2020 Apr; 120(4):599-606. PubMed ID: 32185782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration.
    Schön K; Pestel S; Riedesel J; Seyfert-Brandt W; Claar P; Herzog E; Rezvani-Sharif A; Ponnuswamy P; Nolte MW
    J Thromb Haemost; 2024 Oct; 22(10):2713-2723. PubMed ID: 39019440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
    Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
    J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.